Bortezomib patent

On March 14, the Social Security Bureau of Ningxia Hui Autonomous Region issued the Rules for Handling Serious Illness Insurance for Urban and Rural Residents in Ningxia Hui Autonomous Region (Ning Social Security Fa [2016] No.7) and the Drug List of Serious Illness Insurance for Urban and Rural Residents in Ningxia Hui Autonomous Region (Ning Ren She Fa [2016] No.23), which included velcade in the serious illness of urban and rural residents. This is the second time that velcade has been included in the scope of medical insurance after the Hunan Provincial Department of Human Resources and Social Security and the Health Planning Commission issued a document this year 1 month to include bortezomib (velcade) in the scope of serious illness insurance. So far, Inner Mongolia, Qingdao, Shenzhen and other provinces, autonomous regions and municipalities have launched this measure to benefit the people.

On March 8, Li Bin, director of the National Health Planning Commission, answered questions from reporters during the two sessions. In view of the fact that some patented drugs and imported drugs are too expensive for ordinary people to use, he said that the Health Planning Commission has begun to take measures to start national negotiations with five drugs as pilots, and the decline of these drugs may be more than 50%. Among these five drugs, lenalidomide ranks first. At present, the domestic sales price of lenalidomide is 59,000 yuan (25mg×2 1 capsule/box) and 46,000 yuan (10mg×2 1 capsule/box) respectively, and the average annual drug treatment cost of patients is 600,000-700,000 yuan. After the price reduction, these drugs may gradually enter the list of major illness insurance drugs in various places.

Attached to the Provisions on Handling Serious Illness Insurance for Urban and Rural Residents in Ningxia Hui Autonomous Region (No.7 of Ning Social Security [2065438+06])